How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Blood Collection Manager Market
- By Component: Software, Services
- By Deployment Mode: On-Premise, Cloud-Based
- By End User: Hospitals, Diagnostic Laboratories, Blood Banks, Research Institutes
- By Functionality: Inventory Management, Donor Management, Sample Tracking, Quality Control, Reporting and Analytics
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Software leads By Component at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 265 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.158 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.166 →
Full report · locked preview
Everything inside the Blood Collection Manager Market report
A complete, evidence-based study - 11 chapters and 111 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Component 2
Deployment Mode 2
End User 4
Functionality 5
Companies profiled
Terumo Corporation
Becton Dickinson and Company (BD)
Greiner Bio-One International GmbH
Sartorius AG
Haemonetics Corporation
Pall Corporation (Danaher)
Fresenius Kabi
Nipro Corporation
Sarstedt AG & Co.
B. Braun Melsungen AG
Ortho Clinical Diagnostics
Sysmex Corporation
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Terumo Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Becton Dickinson and Company (BD)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Greiner Bio-One International GmbH
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Sartorius AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Haemonetics Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Pall Corporation (Danaher)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Fresenius Kabi
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Nipro Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Sarstedt AG & Co.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →B. Braun Melsungen AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Ortho Clinical Diagnostics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Sysmex Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Bio-Rad Laboratories
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Abbott Laboratories
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Siemens Healthineers
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →
Global · 2025–2033
$8,015M by 2033 · 11.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Software75.6
- Services24.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,125M → $2,500M · 10.5%
Europe$784.1M → $1,829M · 11.2%
Asia Pacific$715.9M → $1,826M · 12.4%
Latin America$443.2M → $1,018M · 10.9%
Middle East and Africa$340.9M → $744.0M · 10.2%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →11.242026
11.232027
11.252028
11.262029
11.292030
11.282031
11.312032
11.312033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Terumo Corporation21.4
- Becton Dickinson and Company (BD)17.8
- Greiner Bio-One International GmbH12.8
- Sartorius AG6.6
- Haemonetics Corporation7.1
- Pall Corporation (Danaher)6.4
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Component28.7%
Deployment Mode27.9%
End User17.9%
Functionality25.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.6
- Europe23.1
- Asia Pacific23.1
- Latin America12.9
- Middle East and Africa9.4
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Terumo Corporation | 78 | 77 | 89 | 88 | 86 | 85 | 84 |
| Becton Dickinson and Company (BD) | 84 | 90 | 84 | 87 | 74 | 80 | 83 |
| Greiner Bio-One International GmbH | 62 | 69 | 68 | 75 | 82 | 85 | 74 |
| Sartorius AG | 69 | 73 | 72 | 79 | 78 | 74 | 74 |
| Haemonetics Corporation | 73 | 60 | 68 | 62 | 74 | 73 | 68 |
| Pall Corporation (Danaher) | 49 | 48 | 49 | 48 | 60 | 59 | 52 |
| Fresenius Kabi | 44 | 51 | 59 | 41 | 56 | 55 | 51 |
| Nipro Corporation | 40 | 47 | 42 | 44 | 43 | 55 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Terumo Corporation
- Becton Dickinson and Company (BD)
- Greiner Bio-One International GmbH
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Terumo Corporation | ✓ | ◐ | ◐ | ✓ | ✓ | ✓ |
| Becton Dickinson and Company (BD) | ✓ | ◐ | ✓ | ✓ | ✓ | ◐ |
| Greiner Bio-One International GmbH | − | − | ✓ | ✓ | ◐ | ◐ |
| Sartorius AG | ◐ | ◐ | ✓ | ◐ | ✓ | ◐ |
| Haemonetics Corporation | ◐ | − | ◐ | ◐ | ✓ | ✓ |
| Pall Corporation (Danaher) | ◐ | − | ◐ | ◐ | − | ◐ |
| Fresenius Kabi | − | − | − | − | ◐ | ◐ |
| Nipro Corporation | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Terumo Corporation84
2Becton Dickinson and Company (BD)83
3Greiner Bio-One International GmbH74
4Sartorius AG74
5Haemonetics Corporation68
6Pall Corporation (Danaher)52
7Fresenius Kabi51
8Nipro Corporation45
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Terumo CorporationBecton Dickinson and Company (BD)
Challenger3
Strong scale, closing on the leaders.
Greiner Bio-One International GmbHSartorius AGHaemonetics Corporation
Niche3
Specialists in a single segment or region.
Pall Corporation (Danaher)Fresenius KabiNipro Corporation
Go-to-market strategy
Land Component in North America, then scale across Blood Collection Manager Market — a $365M beachhead inside a $5.84B market.
Beachhead (SOM)$365Mobtainable near-term
Serviceable (SAM)$2.02Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Software
Best fit — highest urgency & budget in Component.
Economic buyer76 fit
Services
Strong fit — clear ROI and a fast path to value.
End user67 fit
Enterprise buyers
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Component in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Deployment Mode & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel29%
Digital / self-serve20%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Component leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Blood Collection Manager Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified46%
Sales qualified21%
Evaluation13%
Closed-won7%
$13.4KCAC
$69KLTV
5.2:1LTV : CAC
< 2 moCAC payback
Investment thesis
Blood Collection Manager Market is a durable-growth opportunity — $7.86B by 2033, compounding at 8.6%.
TAM · 2025$4.06Btoday
TAM · 2033$7.86Bforecast
CAGR8.6%2027–2033
Cumulative$52.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.86BTotal addressable market
SAM$2.94BServiceable available market
SOM$602MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.6% CAGR
Demand compounds through 2033, outpacing GDP across Component.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Component moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.86BLarge & growingTAM by 2033 at 8.6% CAGR
$2.94BServiceable nowreachable with today’s model
$602MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.13BBear5.6% CAGR
$7.86BBase8.6% CAGR
$10.1BBull11.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Deployment Mode optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Blood Collection Manager Market — a $6.76B market by 2033. Plan: grow share from 8.3% to 17.2%.
Market size · 2033$6.76Btotal addressable
Market CAGR11.2%2027–2033
Target share17.2%from 8.3% today
Revenue ambition$1.16Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.3% | 17.2% | Behind |
| Revenue | $544M | $1.16B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 28.3% | 41.9% | Behind |
| Customer retention | 89.5% | 95.6% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Component
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Deployment Mode capability
A defensible second engine — invest in Deployment Mode to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Component share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Deployment Mode
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $154M capacity & capability investment
- Greenlight bolt-on M&A in Deployment Mode
- Authorise North America expansion plan
- Fund R&D program for Component leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAhead
- Input-cost & supply riskAt risk
- Regulatory / policy changeBehind
- Execution & talentOn track
Sales deck · value proposition
Win the Blood Collection Manager Market conversation — a $1.97B market you can size, segment and defend in minutes.
Market size · 2033$1.97Btotal opportunity
Growth3.7%CAGR to 2033
Addressable buyers1,675+accounts in scope
Typical ROI6.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Component
Goal Grow share in Component
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.6×return on cost, year one
< 4 mopayback period
$43K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Terumo CorporationBecton Dickinson and Company (BD)Greiner Bio-One International GmbHSartorius AGHaemonetics CorporationPall Corporation (Danaher)Fresenius KabiNipro Corporation+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Blood Collection Manager Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Blood Collection Manager Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Blood Collection Products for Veterinary Use Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportBlood Collection System Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportBlood Collection Tube for Noninvasive Prenatal Testing (NIPT) Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportBlood Collection Tubes (BCT) Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportBlood Collection Tubes and Vials Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportBlood Component Extractor Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportBlood Conservation Device Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportBlood Conversation System Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportBlood Culture Devices Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportBlood Culture Test Device Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportBlood Dialysis Water Treatment Equipment Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportBlood Disease Drugs Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.